{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:21:10Z","timestamp":1791472870588,"version":"4.3.4"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,25]],"date-time":"2020-01-25T00:00:00Z","timestamp":1579910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,25]],"date-time":"2020-01-25T00:00:00Z","timestamp":1579910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Motif"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>We sought to determine the real-world incidence of and risk factors for vancomycin-associated acute kidney injury (V-AKI) in hospitalized adults with acute bacterial skin and skin structure infections (ABSSSI).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Retrospective, observational, cohort study at ten U.S. medical centers between 2015 and 2019. Hospitalized patients treated with vancomycin (\u2265\u200972\u00a0h) for ABSSSI and \u2265\u2009one baseline AKI risk factor were eligible. Patients with end-stage kidney disease, on renal replacement therapy or AKI at baseline, were excluded. The primary outcome was V-AKI by the vancomycin guidelines criteria.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 415 patients were included. V-AKI occurred in 39 (9.4%) patients. Independent risk factors for V-AKI were: chronic alcohol abuse (aOR 4.710, 95% CI 1.929\u201311.499), no medical insurance (aOR 3.451, 95% CI 1.310\u20139.090), ICU residence (aOR 4.398, 95% CI 1.676\u201311.541), Gram-negative coverage (aOR 2.926, 95% CI 1.158\u20137.392) and vancomycin duration (aOR 1.143, 95% CI 1.037\u20131.260). Based on infection severity and comorbidities, 34.7% of patients were candidates for oral antibiotics at baseline and 39.3% had non-purulent cellulitis which could have been more appropriately treated with a beta-lactam. Patients with V-AKI had significantly longer hospital lengths of stay (9 vs. 6\u00a0days,<jats:italic>p<\/jats:italic>\u2009=\u20090.001), higher 30-day readmission rates (30.8 vs. 9.0%,<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and increased all-cause 30-day mortality (5.1 vs. 0.3%,<jats:italic>p<\/jats:italic>\u2009=\u20090.024)<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>V-AKI occurred in approximately one in ten ABSSSI patients and may be largely prevented by preferential use of oral antibiotics whenever possible, using beta-lactams for non-purulent cellulitis and limiting durations of vancomycin therapy.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s40121-019-00278-1","type":"journal-article","created":{"date-parts":[[2020,1,25]],"date-time":"2020-01-25T06:02:22Z","timestamp":1579932142000},"page":"89-106","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["A Multicenter Evaluation of Vancomycin-Associated Acute Kidney Injury in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections"],"prefix":"10.1007","volume":"9","author":[{"given":"Sarah C. J.","family":"Jorgensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle P.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdalhamid M.","family":"Lagnf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Melvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahil","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad-Daniayl","family":"Shamim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karrine D.","family":"Brade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel P.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerod","family":"Nagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen S.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica K.","family":"Ortwine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Veve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Truong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Rybak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,25]]},"reference":[{"key":"278_CR1","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1001\/archinte.168.14.1585","volume":"168","author":"AL Hersh","year":"2008","unstructured":"Hersh AL, Chambers HF, Maselli JH, et al. National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch Intern Med. 2008;168:1585\u201391.","journal-title":"Arch Intern Med"},{"key":"278_CR2","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1086\/656431","volume":"51","author":"TC Jenkins","year":"2010","unstructured":"Jenkins TC, Sabel AL, Sarcone EE, et al. Skin and soft-tissue infections requiring hospitalization at an academic medical center: opportunities for antimicrobial stewardship. Clin Infect Dis. 2010;51:895\u2013903.","journal-title":"Clin Infect Dis"},{"key":"278_CR3","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.3201\/eid1312.070629","volume":"13","author":"E Klein","year":"2007","unstructured":"Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999\u20132005. Emerg Infect Dis. 2007;13:1840\u20136.","journal-title":"Emerg Infect Dis"},{"key":"278_CR4","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.3201\/eid1509.081228","volume":"15","author":"J Edelsberg","year":"2009","unstructured":"Edelsberg J, Taneja C, Zervos M, et al. Trends in US hospital admissions for skin and soft tissue infections. Emerg Infect Dis. 2009;15:1516\u20138.","journal-title":"Emerg Infect Dis"},{"key":"278_CR5","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.jemermed.2014.12.001","volume":"48","author":"CV Pollack Jr","year":"2015","unstructured":"Pollack CV Jr, Amin A, Ford WT Jr, et al. Acute bacterial skin and skin structure infections (ABSSSI): practice guidelines for management and care transitions in the emergency department and hospital. J Emerg Med. 2015;48:508\u201319.","journal-title":"J Emerg Med"},{"key":"278_CR6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ajic.2010.03.018","volume":"39","author":"KM Itani","year":"2011","unstructured":"Itani KM, Merchant S, Lin SJ, et al. Outcomes and management costs in patients hospitalized for skin and skin-structure infections. Am J Infect Control. 2011;39:42\u20139.","journal-title":"Am J Infect Control"},{"key":"278_CR7","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1093\/cid\/cis527","volume":"55","author":"P Tattevin","year":"2012","unstructured":"Tattevin P, Schwartz BS, Graber CJ, et al. Concurrent epidemics of skin and soft tissue infection and bloodstream infection due to community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2012;55:781\u20138.","journal-title":"Clin Infect Dis"},{"key":"278_CR8","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1056\/NEJMoa055356","volume":"355","author":"GJ Moran","year":"2006","unstructured":"Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355:666\u201374.","journal-title":"N Engl J Med"},{"key":"278_CR9","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/cid\/ciu444","volume":"59","author":"DL Stevens","year":"2014","unstructured":"Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis. 2014;59:147\u201359.","journal-title":"Clin Infect Dis"},{"key":"278_CR10","unstructured":"CDC. Antibiotic resistance threats in the United States, 2019. Atlanta: US Department of Health and Human Services, CDC; 2019."},{"key":"278_CR11","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1017\/ice.2017.177","volume":"38","author":"ME Acree","year":"2017","unstructured":"Acree ME, Morgan E, David MZS. S. aureus infections in Chicago, 2006-2014: increase in CA MSSA and decrease in MRSA incidence. Infect Control Hosp Epidemiol. 2017;38:1226\u201334.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"Suppl 1","key":"278_CR12","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1086\/491709","volume":"42","author":"DP Levine","year":"2006","unstructured":"Levine DP. Vancomycin: a history. Clin Infect Dis. 2006;42(Suppl 1):S5\u201312.","journal-title":"Clin Infect Dis"},{"key":"278_CR13","doi-asserted-by":"crossref","unstructured":"Savoldi A, Azzini AM, Baur D et al. Is there still a role for vancomycin in skin and soft-tissue infections? Curr Opin Infect Dis 2017.","DOI":"10.1097\/QCO.0000000000000432"},{"key":"278_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijantimicag.2015.03.011","volume":"46","author":"C Tsoulas","year":"2015","unstructured":"Tsoulas C, Nathwani D. Review of meta-analyses of vancomycin compared with new treatments for Gram-positive skin and soft-tissue infections: are we any clearer? Int J Antimicrob Agents. 2015;46:1\u20137.","journal-title":"Int J Antimicrob Agents"},{"key":"278_CR15","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/ciq146","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18\u201355.","journal-title":"Clin Infect Dis"},{"key":"278_CR16","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1586\/14787210.5.3.393","volume":"5","author":"S Deresinski","year":"2007","unstructured":"Deresinski S. Vancomycin: does it still have a role as an antistaphylococcal agent? Expert Rev Anti Infect Ther. 2007;5:393\u2013401.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"278_CR17","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1086\/518452","volume":"44","author":"S Deresinski","year":"2007","unstructured":"Deresinski S. Counterpoint: vancomycin and Staphylococcus aureus\u2014an antibiotic enters obsolescence. Clin Infect Dis. 2007;44:1543\u20138.","journal-title":"Clin Infect Dis"},{"key":"278_CR18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2146\/ajhp080434","volume":"66","author":"M Rybak","year":"2009","unstructured":"Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66:82\u201398.","journal-title":"Am J Health Syst Pharm"},{"key":"278_CR19","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1128\/AAC.01568-12","volume":"57","author":"SJ van Hal","year":"2013","unstructured":"van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20\u00a0mg per liter. Antimicrob Agents Chemother. 2013;57:734\u201344.","journal-title":"Antimicrob Agents Chemother"},{"key":"278_CR20","doi-asserted-by":"publisher","first-page":"5475","DOI":"10.1128\/AAC.00168-11","volume":"55","author":"JA Bosso","year":"2011","unstructured":"Bosso JA, Nappi J, Rudisill C, et al. Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial. Antimicrob Agents Chemother. 2011;55:5475\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"278_CR21","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1056\/NEJMoa1800170","volume":"380","author":"W O\u2019Riordan","year":"2019","unstructured":"O\u2019Riordan W, Green S, Overcash JS, et al. Omadacycline for acute bacterial skin and skin-structure infections. N Engl J Med. 2019;380:528\u201338.","journal-title":"N Engl J Med"},{"key":"278_CR22","doi-asserted-by":"publisher","first-page":"3471","DOI":"10.1093\/jac\/dkx329","volume":"72","author":"J Pullman","year":"2017","unstructured":"Pullman J, Gardovskis J, Farley B, et al. Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study. J Antimicrob Chemother. 2017;72:3471\u201380.","journal-title":"J Antimicrob Chemother"},{"key":"278_CR23","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1086\/655827","volume":"51","author":"GR Corey","year":"2010","unstructured":"Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis. 2010;51:641\u201350.","journal-title":"Clin Infect Dis"},{"key":"278_CR24","doi-asserted-by":"publisher","first-page":"4658","DOI":"10.1128\/AAC.49.11.4658-4666.2005","volume":"49","author":"J Breedt","year":"2005","unstructured":"Breedt J, Teras J, Gardovskis J, et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother. 2005;49:4658\u201366.","journal-title":"Antimicrob Agents Chemother"},{"key":"278_CR25","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/ofid\/ofx188","volume":"5","author":"RS Kamath","year":"2018","unstructured":"Kamath RS, Sudhakar D, Gardner JG, et al. Guidelines vs actual management of skin and soft tissue infections in the emergency department. Open Forum Infect Dis. 2018;5:188.","journal-title":"Open Forum Infect Dis"},{"key":"278_CR26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jemermed.2015.01.001","volume":"49","author":"K Mueller","year":"2015","unstructured":"Mueller K, McCammon C, Skrupky L, et al. Vancomycin use in patients discharged from the emergency department: a retrospective observational cohort study. J Emerg Med. 2015;49:50\u20137.","journal-title":"J Emerg Med"},{"key":"278_CR27","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1128\/AAC.00173-11","volume":"55","author":"E Minejima","year":"2011","unstructured":"Minejima E, Choi J, Beringer P, et al. Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients. Antimicrob Agents Chemother. 2011;55:3278\u201383.","journal-title":"Antimicrob Agents Chemother"},{"key":"278_CR28","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.clinthera.2011.12.013","volume":"34","author":"EL Cano","year":"2012","unstructured":"Cano EL, Haque NZ, Welch VL, et al. Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP database. Clin Ther. 2012;34:149\u201357.","journal-title":"Clin Ther"},{"key":"278_CR29","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/cid\/cir124","volume":"52","author":"R Kullar","year":"2011","unstructured":"Kullar R, Davis SL, Levine DP, et al. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis. 2011;52:975\u201381.","journal-title":"Clin Infect Dis"},{"key":"278_CR30","doi-asserted-by":"publisher","first-page":"e01293","DOI":"10.1128\/AAC.01293-17","volume":"61","author":"NA Finch","year":"2017","unstructured":"Finch NA, Zasowski EJ, Murray KP, et al. A Quasi-experiment to study the impact of vancomycin area under the concentration-time curve-guided dosing on vancomycin-associated nephrotoxicity. Antimicrob Agents Chemother. 2017;61:e01293.","journal-title":"Antimicrob Agents Chemother"},{"key":"278_CR31","doi-asserted-by":"crossref","first-page":"e02042","DOI":"10.1128\/AAC.02042-17","volume":"62","author":"MN Neely","year":"2018","unstructured":"Neely MN, Kato L, Youn G, et al. Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing. Antimicrob Agents Chemother. 2018;62:e02042.","journal-title":"Antimicrob Agents Chemother"},{"key":"278_CR32","first-page":"e00883","volume":"61","author":"RK Shields","year":"2017","unstructured":"Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother. 2017;61:e00883.","journal-title":"Antimicrob Agents Chemother"},{"key":"278_CR33","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ijantimicag.2010.10.013","volume":"37","author":"A Wong-Beringer","year":"2011","unstructured":"Wong-Beringer A, Joo J, Tse E, et al. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. Int J Antimicrob Agents. 2011;37:95\u2013101.","journal-title":"Int J Antimicrob Agents"},{"key":"278_CR34","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1177\/1060028017720946","volume":"51","author":"YC Choi","year":"2017","unstructured":"Choi YC, Saw S, Soliman D, et al. Intravenous vancomycin associated with the development of nephrotoxicity in patients with class III obesity. Ann Pharmacother. 2017;51:937\u201344.","journal-title":"Ann Pharmacother"},{"key":"278_CR35","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/cid\/ciw709","volume":"64","author":"B Navalkele","year":"2017","unstructured":"Navalkele B, Pogue JM, Karino S, et al. Risk of acute kidney injury in patients on concomitant vancomycin and piperacillin-tazobactam compared to those on vancomycin and cefepime. Clin Infect Dis. 2017;64:116\u201323.","journal-title":"Clin Infect Dis"},{"key":"278_CR36","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31\u201341.","journal-title":"Nephron"},{"key":"278_CR37","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1007\/s00134-003-1662-x","volume":"29","author":"MM Levy","year":"2003","unstructured":"Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM\/ESICM\/ACCP\/ATS\/SIS international sepsis definitions conference. Intensive Care Med. 2003;29:530\u20138.","journal-title":"Intensive Care Med"},{"key":"278_CR38","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","volume":"120","author":"A Khwaja","year":"2012","unstructured":"Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120:c179\u201384.","journal-title":"Nephron Clin Pract"},{"key":"278_CR39","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377\u201381.","journal-title":"J Biomed Inform"},{"key":"278_CR40","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"key":"278_CR41","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/jac\/dky400","volume":"74","author":"T Cutfield","year":"2019","unstructured":"Cutfield T, Walter H, Hobbs M, et al. Association of the Dundee severity classification with mortality, length of stay and readmission in adult inpatients with cellulitis. J Antimicrob Chemother. 2019;74:200\u20136.","journal-title":"J Antimicrob Chemother"},{"key":"278_CR42","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1001\/jama.2016.0288","volume":"315","author":"CW Seymour","year":"2016","unstructured":"Seymour CW, Liu VX, Iwashyna TJ, et al. Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315:762\u201374.","journal-title":"JAMA"},{"key":"278_CR43","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1093\/jac\/dkq362","volume":"66","author":"C Marwick","year":"2011","unstructured":"Marwick C, Broomhall J, McCowan C, et al. Severity assessment of skin and soft tissue infections: cohort study of management and outcomes for hospitalized patients. J Antimicrob Chemother. 2011;66:387\u201397.","journal-title":"J Antimicrob Chemother"},{"key":"278_CR44","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461\u201370.","journal-title":"Ann Intern Med"},{"key":"278_CR45","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604\u201312.","journal-title":"Ann Intern Med"},{"key":"278_CR46","doi-asserted-by":"publisher","first-page":"R204","DOI":"10.1186\/cc2872","volume":"8","author":"R Bellomo","year":"2004","unstructured":"Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure\u2014definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8:R204\u201312.","journal-title":"Crit Care"},{"key":"278_CR47","doi-asserted-by":"publisher","first-page":"R31","DOI":"10.1186\/cc5713","volume":"11","author":"RL Mehta","year":"2007","unstructured":"Mehta RL, Kellum JA, Shah SV, et al. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11:R31.","journal-title":"Crit Care"},{"key":"278_CR48","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1086\/600884","volume":"49","author":"TP Lodise","year":"2009","unstructured":"Lodise TP, Patel N, Lomaestro BM, et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 2009;49:507\u201314.","journal-title":"Clin Infect Dis"},{"key":"278_CR49","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1001\/jama.2014.12923","volume":"312","author":"SS Magill","year":"2014","unstructured":"Magill SS, Edwards JR, Beldavs ZG, et al. Prevalence of antimicrobial use in US acute care hospitals, May\u2013September 2011. JAMA. 2014;312:1438\u201346.","journal-title":"JAMA"},{"key":"278_CR50","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.2215\/CJN.05920616","volume":"11","author":"A Sinha Ray","year":"2016","unstructured":"Sinha Ray A, Haikal A, Hammoud KA, et al. Vancomycin and the risk of AKI: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2016;11:2132\u201340.","journal-title":"Clin J Am Soc Nephrol"},{"key":"278_CR51","unstructured":"Pfunter A, Wier LM, Steiner C. Costs for hospital stays in the United States, 2010. Healthcare cost and utilization project statistical brief. Agency for healthcare Quality and Research. https:\/\/hcup-us.ahrq.gov\/reports\/statbriefs\/sb146.pdf Accessed 08 June 2019."},{"key":"278_CR52","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1128\/AAC.01602-07","volume":"52","author":"TP Lodise","year":"2008","unstructured":"Lodise TP, Lomaestro B, Graves J, et al. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008;52:1330\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"278_CR53","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.clinthera.2007.06.014","volume":"29","author":"MN Jeffres","year":"2007","unstructured":"Jeffres MN, Isakow W, Doherty JA, et al. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther. 2007;29:1107\u201315.","journal-title":"Clin Ther"},{"key":"278_CR54","doi-asserted-by":"publisher","first-page":"336","DOI":"10.12788\/jhm.2983","volume":"13","author":"S Royer","year":"2018","unstructured":"Royer S, DeMerle KM, Dickson RP, et al. Shorter versus longer courses of antibiotics for infection in hospitalized patients: a systematic review and meta-analysis. J Hosp Med. 2018;13:336\u201342.","journal-title":"J Hosp Med"},{"issue":"361","key":"278_CR55","first-page":"2","volume":"13","author":"B Spellberg","year":"2018","unstructured":"Spellberg B. The maturing antibiotic mantra: \u201cShorter is still better\u201d. J Hosp Med. 2018;13(361):2.","journal-title":"J Hosp Med"},{"key":"278_CR56","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1053\/j.ackd.2015.05.003","volume":"22","author":"T Beben","year":"2015","unstructured":"Beben T, Rifkin DE. GFR estimating equations and liver disease. Adv Chronic Kidney Dis. 2015;22:337\u201342.","journal-title":"Adv Chronic Kidney Dis"},{"key":"278_CR57","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1017\/S0950268810001408","volume":"139","author":"SJ Eells","year":"2011","unstructured":"Eells SJ, Chira S, David CG, et al. Non-suppurative cellulitis: risk factors and its association with Staphylococcus aureus colonization in an area of endemic community-associated methicillin-resistant S. aureus infections. Epidemiol Infect. 2011;139:606\u201312.","journal-title":"Epidemiol Infect"},{"key":"278_CR58","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/MD.0b013e3181e8d635","volume":"89","author":"A Jeng","year":"2010","unstructured":"Jeng A, Beheshti M, Li J, et al. The role of beta-hemolytic streptococci in causing diffuse, nonculturable cellulitis: a prospective investigation. Medicine (Baltimore). 2010;89:217\u201326.","journal-title":"Medicine (Baltimore)"},{"key":"278_CR59","doi-asserted-by":"publisher","first-page":"809","DOI":"10.3109\/08860229809045178","volume":"20","author":"E Alexopoulos","year":"1998","unstructured":"Alexopoulos E. Drug-induced acute interstitial nephritis. Ren Fail. 1998;20:809\u201319.","journal-title":"Ren Fail"},{"key":"278_CR60","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40121-018-0198-x","volume":"7","author":"SCJ Jorgensen","year":"2018","unstructured":"Jorgensen SCJ, Mercuro NJ, Davis SL, et al. Delafloxacin: place in therapy and review of microbiologic, clinical and pharmacologic properties. Infect Dis Ther. 2018;7:197\u2013217.","journal-title":"Infect Dis Ther"},{"key":"278_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40121-015-0060-3","volume":"4","author":"JM Rybak","year":"2015","unstructured":"Rybak JM, Roberts K. Tedizolid Phosphate: a next-generation oxazolidinone. Infect Dis Ther. 2015;4:1\u20134.","journal-title":"Infect Dis Ther"},{"key":"278_CR62","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1056\/NEJMoa1403789","volume":"372","author":"LG Miller","year":"2015","unstructured":"Miller LG, Daum RS, Creech CB, et al. Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections. N Engl J Med. 2015;372:1093\u2013103.","journal-title":"N Engl J Med"},{"key":"278_CR63","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1001\/jama.2017.5653","volume":"317","author":"GJ Moran","year":"2017","unstructured":"Moran GJ, Krishnadasan A, Mower WR, et al. Effect of cephalexin plus trimethoprim-sulfamethoxazole vs cephalexin alone on clinical cure of uncomplicated cellulitis: a randomized clinical trial. JAMA. 2017;317:2088\u201396.","journal-title":"JAMA"},{"issue":"Suppl 4","key":"278_CR64","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/1469-0691.12463","volume":"20","author":"M Bassetti","year":"2014","unstructured":"Bassetti M, Baguneid M, Bouza E, et al. European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after more than 10\u00a0years of experience with linezolid. Clin Microbiol Infect. 2014;20(Suppl 4):3\u201318.","journal-title":"Clin Microbiol Infect"},{"key":"278_CR65","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1093\/cid\/ciw118","volume":"62","author":"TF Barlam","year":"2016","unstructured":"Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an antibiotic stewardship program: guidelines by the infectious diseases society of america and the society for healthcare epidemiology of America. Clin Infect Dis. 2016;62:e51\u201377.","journal-title":"Clin Infect Dis"},{"key":"278_CR66","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/CCM.0000000000002769","volume":"46","author":"MK Luther","year":"2018","unstructured":"Luther MK, Timbrook TT, Caffrey AR, et al. Vancomycin plus piperacillin-tazobactam and acute kidney injury in adults: a systematic review and meta-analysis. Crit Care Med. 2018;46:12\u201320.","journal-title":"Crit Care Med"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-019-00278-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40121-019-00278-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-019-00278-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T21:43:33Z","timestamp":1665611013000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40121-019-00278-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,25]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["278"],"URL":"https:\/\/doi.org\/10.1007\/s40121-019-00278-1","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,25]]},"assertion":[{"value":"16 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}